KRAS and non-small cell lung carcinoma: Among the 33 enrolled non-G12C KRAS-mutant NSCLC patients, the median PFS was 10.3 months (95% CI: 7.0–15.1), and the median OS was 19.7 months (95% CI: 15.5 to not be evaluated) (Supplementary Fig. 6b, 6c).